美股異動丨阿斯麥盤前跌近5%,Q1淨銷售額、新訂單及Q2銷售指引均遜預期
阿斯麥(ASML.US)盤前跌近5%報928.95美元。消息面上,當地時間週三,阿斯麥公佈一季度業績顯示,淨銷售額同比下降21.6%至52.9億歐元,低於預期的54.7億歐元;淨利潤同比下滑37.4%達12.2億歐元,超出預期的10.7億歐元;新訂單為36.1億歐元,不及預期的46.3億歐元。二季度銷售指引同樣遜預期,阿斯麥預計二季度淨銷售額為57-62億歐元,預期值為64.6億歐元,二季度毛利率達50%-51%。不過,阿斯麥對2024年的銷售增長展望維持不變,預計2024年銷售額與上年基本持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.